Emory University · company speakers →
Dr. Shannon Meeks will discuss the role of immune tolerance induction (ITI) in the emicizumab era. The ability to prevent bleeding in hemophilia A with a non-factor product has allowed the opportunity to reassess treatment strategies in patients with inhibitors. Dr. Meeks will also discuss the current landscape for tolerance and whether emicizumab and ITI are partners or foes.
Is this you? Claim this profile →
No public contact links on file.
Sourcing speakers for your event?
Browse the speaker directory →